Droxidopa capsules

DRUG2 trials

Sponsors

H. Lundbeck A/S, Giuseppe Cullaro, MD

Conditions

Acute Kidney InjuryCirrhosisDecompensated Cirrhosis of LiverSymptomatic Neurogenic Orthostatic Hypotension

Phase 2

Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury

RecruitingNCT06937307

Giuseppe Cullaro, MDAcute Kidney Injury, Cirrhosis, Decompensated Cirrhosis of Liver

Start: 2025-05-27End: 2028-12-31Target: 75Updated: 2026-08-19

Phase 4

Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension

CompletedNCT02586623

H. Lundbeck A/SSymptomatic Neurogenic Orthostatic Hypotension

Start: 2016-02-11End: 2022-09-09Updated: 2023-08-23

Related Papers

Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment.

2022-02-026 citations

Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension

BMC Neurology2017-05-1280 citations